WW International Financials - Benzinga

WW International Inc

WWNASDAQ

Trade with Public

Trade with Public

$14.36

0.372.61%

近くで: Sep 25, 5:00 PM EST

$14.60

0.241.68%

時間外: 7:21 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

WW International Financials

WW International (WW) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
WW International Affirms FY2026 Sales Guidance of $620.000M-$635.000M vs $632.183M Est

WW International (NASDAQ:WW) affirms FY2026 sales outlook from $620.000 million-$635.000 million to $620.000 million-$635.000 million vs $632.183 million estimate.

Benzinga Newsdesk

PRO
WW International Q2 EPS $1.41 Beats $0.97 Estimate, Sales $162.324M Beat $159.150M Estimate

WW International (NASDAQ:WW) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $0.97 by 45.36 percent. This is a 98.59 percent increase over earnings of $0.71 per share from the

Benzinga Newsdesk

WW International Q1 Revenue Beats, But Subscriber Decline, EBITDA Loss Sink Shares

WW shares drop after the company reports a wider quarterly loss, weaker behavioral subscriber trends and negative adjusted EBITDA.

Akanksha Bakshi

PRO
WW International Q1 EPS $(5.20) Misses $(2.51) Estimate, Sales $168.261M Beat $158.550M Estimate

WW International (NASDAQ:WW) reported quarterly losses of $(5.20) per share which missed the analyst consensus estimate of $(2.51) by 107.17 percent. This is a 471.43 percent decrease over losses of $(0.91) per share

Benzinga Newsdesk

PRO
WW International Affirms FY2026 Sales Guidance of $620.000M-$635.000M vs $633.445M Est

WW International (NASDAQ:WW) affirms FY2026 sales outlook from $620.000 million-$635.000 million to $620.000 million-$635.000 million vs $633.445 million estimate.

Benzinga Newsdesk

WW Shares Surge On Heels Of Q4 Report, CEO Says Weight Watchers Is 'Evolving' In GLP-1 Era

WW stock jumps after WeightWatchers beats revenue estimates and expands clinical weight-loss services while growing clinical subscribers.

Akanksha Bakshi

© 2026 Benzinga | All Rights Reserved